ZAI LAB LIMITED (ZLAB) Current Ratio
- Current ratio · latest quarter: Value 2.13×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 2.13× | Current assets / current liabilities. $914.04M ÷ $428.58M ≈ 2.13× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 914.04M USD | Assets, Current |
| Current obligations | 428.58M USD | Liabilities, Current |
| Cash and equivalents | 607.52M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | 69.59M USD | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 90.89M USD | Inventory, Net |
| Payables | 136.69M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $914.04M | $428.58M | $607.52M | (m) | $69.59M | $90.89M | $136.69M | (m) | 2.13× |
| 2026-03-31 | $944.73M | $392.98M | $651.32M | (m) | $54.07M | $85.96M | $126.17M | (m) | 2.40× |
| 2025-12-31 | $1.02B | $416.17M | $679.57M | (m) | $106.12M | $74.75M | $141.61M | (m) | 2.45× |
| 2025-09-30 | $1.03B | $359.77M | $717.15M | (m) | $85.38M | $67.14M | $99.71M | (m) | 2.87× |
| 2025-06-30 | $1.03B | $331.50M | $732.16M | (m) | $88.50M | $61.70M | $107.36M | (m) | 3.12× |
| 2025-03-31 | $1.04B | $319.81M | $757.26M | (m) | $76.56M | $53.05M | $103.02M | (m) | 3.26× |
| 2024-12-31 | $1.05B | $299.38M | $449.67M | (m) | $85.18M | $39.88M | $100.91M | (m) | 3.51× |
| 2024-09-30 | $860.55M | $286.31M | $616.09M | (m) | $49.97M | $39.55M | $120.65M | (m) | 3.01× |
| 2024-06-30 | $869.92M | $251.72M | $630.05M | (m) | $69.64M | $41.85M | $127.34M | (m) | 3.46× |
| 2024-03-31 | $888.64M | $192.11M | $650.78M | (m) | $60.42M | $37.85M | $88.12M | (m) | 4.63× |
| 2023-12-31 | $939.61M | $203.07M | $790.15M | (m) | $59.20M | $44.83M | $112.99M | (m) | 4.63× |
| 2023-09-30 | $959.73M | $124.90M | $788.81M | (m) | $41.60M | $44.23M | $55.02M | (m) | 7.68× |
| 2023-06-30 | $1.02B | $133.35M | $859.15M | (m) | $47.28M | $36.35M | $67.03M | (m) | 7.63× |
| 2023-03-31 | $1.07B | $124.56M | $879.84M | (m) | $43.35M | $38.41M | $66.36M | (m) | 8.61× |
| 2022-12-31 | $1.12B | $139.84M | $1.01B | (m) | $39.96M | $31.62M | $65.97M | (m) | 8.04× |
| 2022-09-30 | $1.21B | $155.55M | $1.12B | (m) | $27.74M | $29.13M | $90.11M | (m) | 7.78× |
| 2022-06-30 | $1.34B | $168.88M | $680.82M | (m) | $27.05M | $23.34M | $108.44M | (m) | 7.91× |
| 2022-03-31 | $1.39B | $154.91M | $846.96M | (m) | $33.39M | $20.29M | $98.16M | (m) | 8.99× |
| 2021-12-31 | $1.50B | $192.90M | $964.10M | (m) | $47.47M | $18.95M | $126.16M | (m) | 7.78× |
| 2021-09-30 | $1.62B | $112.01M | $1.40B | (m) | $21.02M | $12.49M | $51.41M | (m) | 14.45× |
| 2021-06-30 | $1.81B | $193.92M | $1.77B | (m) | $18.03M | $11.11M | $125.62M | (m) | 9.33× |
| 2021-03-31 | $1.05B | $92.66M | $1.01B | (m) | $8.81M | $12.63M | $41.41M | (m) | 11.32× |
| 2020-12-31 | $1.22B | $98.04M | $442.12M | (m) | $5.17M | $13.14M | $62.64M | (m) | 12.40× |
| 2020-06-30 | $484.88M | $56.55M | $258.60M | (m) | $7.02M | $6.57M | $32.39M | (m) | 8.57× |
| 2019-12-31 | $292.46M | $46.63M | $75.93M | (m) | $3.79M | $6.00M | $22.66M | (m) | 6.27× |
| 2019-09-30 | $329.30M | $41.05M | $68.71M | (m) | $3.92M | $889.43K | $20.46M | (m) | 8.02× |
| 2018-12-31 | $269.14M | $48.84M | $62.95M | (m) | $90.00K | $4.00K | $37.43M | (m) | 5.51× |
| 2017-12-31 | $230.61M | $12.07M | $229.66M | (m) | (m) | (m) | $8.97M | (m) | 19.11× |
| 2016-12-31 | $84.09M | $5.17M | $83.95M | (m) | (m) | (m) | $523.34K | (m) | 16.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |